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A report of the third Interactome Networks Conference,
Hinxton, UK, 29 August-1 September 2007.
Complex systems are often networked, and biology is no
exception. Following on from the genome sequencing projects,
experiments show that proteins in living organisms are highly
connected, which helps to explain how such great complexity
can be achieved by a comparatively small set of gene products.
At a recent conference on interactome networks held outside
Cambridge, UK, the most recent advances in research on
cellular networks were discussed. At previous meetings in this
series we heard much about the abstract properties of
biological networks, often with little application to day-to-day
biology, and the achievement of amazing milestones such as
the first drafts of human interactomes or the completion of
affinity-purification screens for protein complexes in yeast.
This year’s conference was more down to earth, focusing on
identifying the strengths and weaknesses of currently resolved
interaction networks and the techniques used to determine
them - reflecting the fact that the field of mapping interaction
networks is maturing.
Detecting challenging proteins and interaction
types
One of the key points that kept popping up during the
meeting was the need to identify and establish a reliable set
of protein interactions, including binary pairs and larger
assemblies. These could then be used to validate the results
produced by each technique and, perhaps more importantly,
to identify the advantages and drawbacks of each technique.
Marc Vidal (Dana-Farber Cancer Institute, Boston, USA)
presented the results of a thorough benchmarking of the
yeast two-hybrid system. He convincingly showed that
interactions discovered in high-throughput yeast two-hybrid
screens were as reliable as those from individual experi-
ments, and that their accuracy, in terms of the false-positive
rate, was also comparable to that of affinity-purification
assays. He and Pascal Braun (Dana-Farber Cancer Institute)
also showed that in an ideal scenario a two-hybrid
experiment would be able to detect roughly 25% of the total
number of possible interactions. However, the typical cover-
age of a single screen is only about 10%, and one would have
to repeat the same experiment six times to reach the upper
coverage limit of 25%. These criteria were used to estimate
that there would be approximately 280,000 protein-protein
binary interactions in humans, without including splice
variants. Anne-Claude Gavin (European Molecular Biology
Laboratory, Heidelberg, Germany) addressed similar
questions for yeast protein interactions discovered by
affinity purification coupled to mass spectrometry (MS). She
showed that the reproducibility rate of purifications is about
69% and that, although she and her colleagues were able to
see proteins from all functional classes and a wide range of
copy numbers, there was a bias towards structural proteins
and highly abundant proteins. Overall, they were able to
detect roughly 60% of the proteins known to be expressed in
exponentially growing yeast.
Both these studies highlighted the fact that no single
technique will detect everything, and that to comprehen-
sively chart an interactome network these methodologies
and others will have to be combined. Moreover, some
proteins are inherently underrepresented in all large-scale
screens reported, mainly due to difficulty in their bio-
chemical manipulation. This is the case for membrane and
extracellular proteins, many of which have no binding
partners reported so far. Gavin Wright (Wellcome Trust
Sanger Institute, Hinxton, UK) presented a novel in vitro
binding assay designed to detect low-affinity interactions
between extracellular proteins. This protocol, called an
avidity-based extracellular interaction screen (AVEXIS),
enables the identification of hitherto unknown cell-surface
receptor-ligand pairs and will help to reveal the systems that
cells use to communicate with each other.
Igor Staljar (University of Toronto, Canada) introduced a
modification of the yeast two-hybrid system designed todetect interactions that include integral membrane proteins,
with special emphasis on those of pharmacological interest.
The new membrane yeast two-hybrid methodology (MYTH)
involves constructs in which the two halves of a ubiquitin
molecule are fused to two potentially interacting proteins, at
least one of which is membrane bound, and a transcription
factor is inserted after the ubiquitin. If the two proteins
interact, a complete ubiquitin molecule is reconstituted and
the transcription factor is cleaved by ubiquitin-specific
proteases and released to switch on a reporter gene. Staljar
also showed how this methodology has been applied to
investigate complex cell signaling processes and membrane
trafficking using collections of membrane proteins. In this
context, Gavin showed how a slight variation in the protocol
used in her large-scale affinity-purification screen in yeast
enabled the retrieval of 340 membrane proteins out of 628
tagged, including some integral membrane complexes such
as the Q/t-SNARE. All the methods mentioned above have
been designed with the aim of using them in a high-
throughput fashion and need very little modification to be
fully automatable.
It also became clear at the meeting that current methods
not only miss certain types of proteins but also miss specific
types of interactions. All the techniques currently used in
large-scale studies are poor at detecting very transient
interactions or those that depend on posttranslational
modifications, and efforts to remedy this were reported. In
these difficult cases computational methods seem to be
useful. Rune Linding (Mount Sinai Hospital, Toronto,
Canada) and colleagues have exploited the modularity
observed in signaling networks to predict specific
phosphorylation patterns in DNA-damage responses, thus
deciphering some of the most elusive regulatory networks
in vivo. Linding also reported the experimental validation
of some of the predicted relationships by
immunoprecipitation and MS analyses. Richard Edwards
(University College Dublin, Ireland) showed how
computational approaches can be used to discover new
motifs in peptide-mediated transient protein interactions.
Proteins are not the only molecules in living organisms and
so it makes little sense to study protein interactions in
isolation. We now have the experimental tools to investigate
protein interactions with other molecules in a systematic
way. Martha Bulyk (Harvard Medical School, Boston, USA)
and Marian Walhout (University of Massachusetts Medical
School, Boston, USA) presented two different systems for
studying protein-DNA interactions to reveal the mechanisms
underlying regulatory transcriptional networks. Bulyk intro-
duced a DNA microarray-based in vitro assay that enables
high-throughput characterization of the binding sites for
specific transcription factors in DNA and identifies the
combinatorial co-regulation of certain genes. Walhout
reported the development of an in vivo yeast one-hybrid
system for the high-throughput identification of interactions
between transcription factors and their target genes in
Caenorhabditis elegans.
Quantitative proteomics and mass spectrometry
The amount and quality of the data yielded by high-through-
put protein-interaction experiments are also being extended.
For example, Etienne Formstecher (Hybrigenics, Paris,
France) presented a Drosophila interaction-mapping project
using domain-based yeast two-hybrid technology, which is
designed to throw light on cell signaling in human cancer.
This technique enables identification of the specific domains
in the interacting proteins that are responsible for the
binding and extends the scope of the classic yeast two-hybrid
experiment, which is only able to detect whether two full-
length proteins interact.
Probably the most spectacular advances in this area are
related to MS. Hitherto, MS has been used in combination
with pull-down assays to identify which proteins are purified
together. The field has now advanced to a point where MS
can confidently provide information about the composition
of functional sub-complexes, protein stoichiometry and even
dissociation constants. Albert Heck (Utrecht University,
Utrecht, The Netherlands) reported innovative MS-based
approaches to disentangle the three-dimensional assembly
of components and the dynamic composition of several
complexes (for example, RNA polymerases or the exosome, a
protein complex involved in RNA processing and degrada-
tion). He also showed how the gradual dissociation of
complex components can be used to estimate dissociation
constants and cooperative effects between proteins.
Matthias Mann (Max Planck Institute for Biochemistry,
Martinsreid, Germany) demonstrated the power of his newly
developed quantitative proteomics technique for MS -
stable-isotope labeling with amino acids in cell culture
(SILAC) - to remove false positives in protein-interaction
networks and to reveal kinetic aspects of the control of
signaling by protein phosphorylation. The abundance of
high-quality data confirms that quantitative MS is here to
stay and is already making key contributions to most areas
in proteomics. The improved methods and new data should
allow the field to move on from the static representation of
interaction networks to the more realistic and dynamic
models necessary for a systems-biology approach.
Improving data gathering and dissemination
Being able to trace, verify and clarify the experiments that
generate interaction network data is as important as the data
themselves. Sandra Orchard (European Bioinformatics
Institute, Hinxton, UK) presented the MIMIx initiative
(minimum information requirement to report a molecular
interaction experiment) as an attempt to standardize the
data that any interaction discovery experiment should
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data producers, which guarantees their wide acceptance, and
will hopefully result in publications of increased clarity and a
rapid, systematic capture of molecular-interaction data in
public databases. Advances and updates in the data
repositories were reported by Jyoti Khadake (European
Bioinformatics Institute) and Andrew Chatr-aryamontri
(University of Rome Tor Vergata, Rome, Italy), who
presented the IntAct [http://www.ebi.ac.uk/intact] and
MINT [http://mint.bio.uniroma2.it/mint] databases, respec-
tively, two of the world’s largest warehouses of protein-
interaction data. It was good news indeed to hear that they
have agreed to cooperate within the International Molecular
Exchange (IMEX) consortium, together with the Database of
Interacting Proteins (DIP) and the Munich Information
Center for Protein Sequences protein-interaction data
resource (MPact), and to cover more journals with manual
curation - a tremendous amount of work.
Biophysically possible versus biologically
relevant
Virtually all the high-throughput attempts to chart inter-
actome networks detect interactions between macro-
molecules that are biophysically possible - which does not
necessarily mean that they occur in the living cell. Nature
has many control mechanisms that can prevent bio-
physically plausible interactions, such as subcellular
compartmentalization, different times of expression and
tight control of specificity via competition. Christopher
Sanderson (University of Liverpool, UK) addressed this
question in an analysis of more than 8,500 putative
interactions between E2 ubiquitin-conjugating enzymes
and E3 ubiquitin ligases within the human ‘ubiquitome’.
The resulting gene-family-specific high-density protein-
interaction map was combined with information from
mutants that perturb true E2-E3 interactions and with
bioinformatics analyses, which revealed that, although
many spurious interactions are possible, proteins show
clear preferences for specific partners. Linding also
emphasized the importance of biological control
mechanisms of interaction specificity. He showed that, for
instance,  to consider the biological scenario surrounding
an interaction increases the computational ability to assign
in vivo substrate specificity in phosphorylation events to
around 60-80%.
A very encouraging message from the meeting is that,
although being error-prone and incomplete, the data and
models generated so far have proved useful in under-
standing biological processes and have triggered innovative
biomedical applications. Andrea Califano (Columbia
University, New York, USA) showed how the existing data,
combined with complex Bayesian integration approaches
and a few biochemical validations, has enabled a first draft
of the protein-interaction network in the human B
lymphocyte. This has led to the identification of deregulated
interactions in specific pathological or physiological
phenotypes and helped to identify some key effectors in
normal physiology and the causal lesions in several well-
studied B-cell malignancies.
Towards a visual proteomics
“We know about molecules; we know about cells and
organelles; but the stuff in between is messy and mysterious.”
In his keynote lecture on how to bridge the resolution gap
between single molecules and whole cells, Wolfgang
Baumeister (Max Planck Institute for Biochemistry) was
quoting from an article by the writer Philip Ball. Classical
structural biology techniques, such as X-ray crystallography
or single-particle electron microscopy, can provide atomic-
level information in the angstrom range about small proteins
and large macromolecular complexes. Cell biology has the
necessary tools to study cellular organization with a reso-
lution approaching 150 nanometers, but the nanometre range
is completely uncharted territory. Baumeister discussed
electron tomography as a tool for visualizing large molecular
machines and their associations in supramolecular struc-
tures in their functional environment. His exciting talk was
very well received by an audience that saw the power of
combining interaction discovery and structural biology, in
what he calls “visual proteomics”, to construct a pseudo-
atomic atlas of the cellular inner space. Starting from
another viewpoint - abstract representations of interaction
networks - Ewan Birney (European Bioinformatics Institute)
presented a Java-based navigation tool for moving across
the biological pathways defined in the Reactome database.
The tool is easily adapted to work on any network, and it is
easy to imagine how to combine this technology with high-
and medium-resolution three-dimensional structures of
macromolecular complexes and whole-cell tomograms to
create ‘Google maps’. By highlighting blurry regions where
data are lacking, these navigable models will help to identify
the needed research.
It is fascinating to see how the interactome networks
research community is evolving in response to new
scientific and technological advances. We are clearly on
a journey analogous to the one that started 15 years ago
and ended with the first draft of the human genome. At
last year’s meeting, Richard Gibbs, one of the fathers of
the human genome project, suggested that we focus on
methods development, automation, data gathering and
quality checks - which we have done to a large extent.
This year, Ed Harlow (Harvard Medical School, Boston,
USA) pointed out the need to team up and to cooperate
as a real consortium to tackle a model system to
completion. Who knows, if we follow his advice, this
might be the beginning of the interactome networks era.
I look forward to seeing where we have got to at the next
meeting in 2008.
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